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1. Introduction
Organ regeneration technologies aim to restore the original structure and functionality of a
diseased organ. In general, healing responses within mammals are characterized by fibrosis
and scar tissue formation, not regeneration. Nevertheless, developing mammalian fetuses
during the first trimester present wound healing without fibrosis and scar tissue formation
(Adzick and Lorenz, 1994). Additionally, compensatory hyperplasia of mammalian kidney or
liver secondary to partial nephrectomy or hepatectomy, remodeling of epidermis or bone
consequent to injury and regeneration of limb digit tips in humans and mice post-amputation
are all examples of regenerative outcomes in adult mammals indicative of an innate regener‐
ative potential within adult mammals (reviewed by Roy and Gatien, 2008).
However, model organisms such as Hydra, planaria, zebrafish, Xenopus and urodeles (sala‐
manders) present the clearest examples of regenerative outcomes secondary to injury. In these
systems, cell-based strategies harnessing pluripotent and tissue specific stem cells as well as
dedifferentiation have been leveraged to mediate the regeneration of whole limbs and organs
(reviewed by Tanaka and Reddien, 2011). Systematic experimentation with limb regeneration
in urodeles has permitted the decipherment of key mechanistic pathways of regeneration at
the molecular level. Activation of salient signaling cascades including p53, TGF-β, Delta, ppRB
and Wnt/β-catenin have all been associated with limb regeneration (reviewed by Roy and
Gatien, 2008). These signaling pathways catalyze a sequence of instructive interactions
between mesodermal and ectodermal cell populations that are ultimately responsible for
lineage specification (reviewed by Wessels, 1977). In addition, the methodical depletion of
macrophages within the first 24 hours subsequent to limb amputation in urodeles has been
demonstrated to lead to permanent failure of limb regeneration, extensive fibrosis and dis-
regulation of transcriptional patterns associated with synthesis of extra-cellular matrix (ECM)
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components (Godwin et al., 2013). This specific sequence of cellular events associated with
regeneration of the urodele limb as defined below recapitulates aspects of embryonic organo‐
genesis and may serve as a model system for establishing the existence of similar pathways in
mammals:
Stages in regeneration of urodele limb secondary to amputation:
1. The open wound is enclosed by wound epithelium to form a permissive epithelial
structure referred to as the apical ectodermal cap (AEC).
2. Up-regulation of matrix metallo-proteinase (MMP) expression catalyzes structural
reorganization of the ECM.
3. Dedifferentiation of cell populations takes place proximal to the plane of amputation.
4. Proliferation and migration of dedifferentiated cells is observed under the AEC.
5. Induction of a blastema, a mass of mesenchymal cells that will eventually re-differentiate
to create the new muscles, bones, nerves and tendons required to regenerate a functional
limb.
An understanding of these stages has already been applied to accelerate regenerative outcomes
in mammals. For example, application of MMP1 to digit remnants of adult mice with ampu‐
tation at the mid-second phalanx significantly improved regeneration of soft tissue and
observed rates of wound closure. More multi-potent progenitor cells, capillary vasculature
and neuromuscular related tissues were also noted (Mu et al., 2013). Furthermore, recent data
on regenerative outcomes in mammals from tissue engineering of bladder, esophagus and
intestine provides additional evidence of the existence of a regenerative pathway in adult
mammals mimicking aspects of that observed in urodeles, including formation of a neo-
blastema. This regenerative pathway is characterized by a dependence on adequate vascula‐
rization and innervation at the site of regeneration. Importantly, these observations provide
insight into a potential mechanism of action for tissue engineered products characterized
broadly as instructive signaling between mesenchymal cells of the regenerative construct and
host epithelial cell populations. This insight may be harnessed to facilitate development of
novel neo-organ products. Here, we review recent progress in regeneration of tubular organs
with a particular focus on the gastrointestinal tract that highlights how Tengion’s Organ
Regeneration PlatformTM may harness these fundamental regenerative pathways.
2. Tengion’s organ regeneration platform
Tubular organ regeneration involves a specific, temporal sequence of cellular infiltration,
vasculogenesis, neurogenesis and the defined differentiation of mucosal, stromal and paren‐
chymal laminar tissue architectures (reviewed by Basu and Ludlow, 2010). Strategies for organ
and tissue regeneration must therefore achieve the dual objectives of triggering a true regen‐
erative response while ameliorating any tendency towards fibrotic repair. The methodology
first pioneered for regeneration of the bladder may serve as a foundational platform for the
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regeneration of any tubular organ including penis, vagina, lung, small intestine, stomach and
vessels.
Illustrated by Tengion’s Neo-Bladder AugmentTM (NBA), this approach initially applied
committed cell populations of target organ sourced (bladder)-derived urothelial cells (UC) and
smooth muscle cells (SMC) complexed with a biodegradable, synthetic scaffold to trigger de
novo organogenesis (Oberpenning et al., 1999). The NBA is composed of a biodegradable
scaffold seeded with autologous, bladder derived UC and SMC. During implantation, the NBA
is wrapped with omentum to facilitate vascularization of the developing neo-organ (Figure
1). This is a critical requirement for successful organ regeneration (Basu & Ludlow, 2010; Basu
& Ludlow, 2011; Basu & Ludlow, 2012). Analysis of the matured construct at the cellular level
highlights committed SMC interacting with polymer fibers of the biodegradable scaffold
(Figure 2). Over time (~3 months), a laminarly organized neo-organ develops. Variations of
this approach have recently been described, and the key methodological elements arising from
these principal recent reports demonstrating in vivo regeneration of neo-bladder or neo-
bladder related tissue has been reviewed in detail (Basu & Ludlow, 2010; Basu & Ludlow, 2011;
Basu & Ludlow, 2012).
reviewed in detail (Basu & Ludl
Figure 1. Tengion Neo-Bladder Augment (NBA) during implantation (left) and subsequent to wrapping with omen‐
tum (right).
Examination of the temporal sequence of neo-bladder regeneration in canine clinical studies
illustrates the dichotomy in outcomes between implantation of acellular and cellularized
scaffolds (Jayo et al., 2008a,b). This distinction is a principal theme of most studies describing
the regeneration of tubular organs. Cell seeded scaffolds mediated a regenerative response
within one month post-implantation, characterized by induction of heavily vascularized,
smooth muscle-like parenchyma. In contrast, acellular scaffolds triggered a principally fibrotic,
reparative outcome characterized by randomly organized collagen fibers with minimal
vascularization. Baseline urodynamics were reconstituted within four months of implantation
with cell seeded scaffolds, whereas the urodynamic profile of animals implanted with acellular
scaffolds remained abnormal throughout the trial period (Jayo et al., 2008a). In a related dog
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study, restoration of tri-laminar bladder wall architecture occurred within three months post-
implantation and normal compliance characteristics of a urinary bladder wall developed by
12 months (Jayo et al., 2008b). Regenerated bladders were functionally and structurally stable
for up to two years post-implantation (Jayo et al., 2008b). Importantly, although the construct
volume was constant at implantation within variably sized dogs, the ratio of the regenerated
bladder’s volume to host body weight adapted to the recipient animal’s size, demonstrating
that the neo-organ responds to homeostatic mechanisms regulating organ volume (Jayo et al.,
2008b).
Although these canine studies utilized both bladder-derived urothelial and smooth muscle
cells, urothelial cells have been shown to not be essential for bladder regeneration, thereby
greatly facilitating process development and commercialization (Basu & Ludlow, 2010). Neo-
urinary constructs seeded only with smooth muscle cells and not urothelial cells nevertheless
catalyze complete regeneration of de novo urinary-like tissue with patent urothelium, presum‐
ably through migration of epithelial cells in trans via urine flow or from neighboring tissue
(Basu et al., 2012a). However, use of bladder-derived smooth muscle cells is problematic in
patients presenting with bladder related malignancies. Therefore, a number of alternate
sources of smooth muscle cells have been investigated. Such alternate cell sources may have
broad application in the regeneration of additional, laminarly organized tubular organs.
Tengion has identified adipose and peripheral blood as alternate sources of smooth muscle
cells usable for induction of neo-urinary tissue (Basu et al., 2011a; Basu et al., 2012a). As with
other early signaling events during organogenesis or regeneration, instructive interactions
between this mesenchymal cell population associated with the regenerative construct and
epithelial cell populations within the host are understood to be critical for observed regener‐
ative outcomes.
Figure 2. SMC interacting with woven mesh of PGA (poly-glycolic acid), a biodegradable polymer. 170X
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3. The need for urinary neo-organs
At its most fundamental level, the bladder is responsible for mediating storage and subsequent
efflux of urine within a dynamically expandable and contractable container. Though relatively
simple in terms of overall histology and structural organization (Figure 3), diseases impacting
the bladder have the potential to significantly affect individual quality of life, resulting in
continual incontinence or inability to effectively void urine as needed. Several congenital
anomalies may result in abnormal bladder development requiring surgical intervention,
including posterior urethral valves, bilateral ectopic ureters, bladder extrophy, cloacal
extrophy, and spina bifida (myelomeningocele). The resultant clinical outcomes include
incontinence and increased risk of renal failure from high pressures in the genito-urinary
system.
Figure 3. Macroscopic (left) and histological (right) organization of the bladder, illustrating tri-laminar cellular archi‐
tecture of this hollow, muscular organ. Reproduced from Wikipedia Commons (Open Access) under terms of Open
Access agreement.
The current standard of therapy for pediatric patients is bladder augmentation through
enterocystoplasty, a procedure which involves the surgical removal of a section of large bowel
that is then connected to the existing bladder to increase compliance, decrease pressure, and
improve overall urine capacity. These surgeries are relatively complex and costly. Even in
patients with good technical outcomes, the procedure is associated with numerous immediate
risks and potential chronic complications. A similar surgical procedure is performed in adults
requiring bladder replacement, typically secondary to the onset of bladder related malignan‐
cies. To this end, cancer of the bladder may be manifested as a broad spectrum of disease
presenting across distinct bladder compartments.
The most common types of bladder cancers originate from the internal epithelial lining of the
bladder, the urothelium. Less common cancers of the bladder may include squamous cell
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carcinoma, adenocarcinoma, sarcoma, and small cell carcinoma. Estimates predict that almost
71,000 new cases of bladder cancer will be diagnosed annually in the USA, with some 14,000
patients succumbing to the disease. Although many patients will have superficial urothelial
tumors involving little or no metastasis within the smooth muscle layer, approximately 25%
of bladder cancers will invade the detrusor musculature, with the majority of these presenting
initially as invasive cancers with metastatic potential.
Invasive cancers often require multi-modality therapy which may involve extirpative surgery,
i.e. radical cystectomy and construction of a urinary diversion. Despite the risk of adverse
effects, there are approximately 10,000 of these procedures performed per year in the United
States, including in 10% of children with congenital bladder abnormalities and 90% of adults
with acquired disorders such as bladder cancer. In some cases of severe bladder cancer or other
pelvic or abdominal cancers, removal of the entire bladder is indicated. In these circumstances,
current standard of care also involves reconstruction of a bladder-like replacement using bowel
tissue. Application of bowel tissue for reconstruction of urinary neo-organs is clearly prob‐
lematic for a number of fundamental reasons, including the fact that bowel is a principally
absorptive organ, whereas bladder is designed to store and excrete urine. Exposure of bowel
tissue to urine or bladder tissue to bowel-derived micro-organisms has the potential to trigger
multiple secondary complications. These may include any of the following:
• Bowel complications. Early complications are usually related to the bowel surgery required
to harvest tissue for reconstructive use and typically consist of leaks, fistulas and obstruc‐
tions. Because vitamin B12 is absorbed in the bowel tissue, loss of this tissue can result in
anemia and neurologic abnormalities. Additionally, mal-absorption of salts and lipids can
lead to diarrhea. Patients with neurogenic bladder are prone to bowel movement problems
even before surgery and the removal of bowel tissue may either exacerbate existing
conditions or create new motility problems. These difficulties further contribute to substan‐
tial physical and psychological morbidity within these patients.
• Absorption issues. Use of bowel tissue often leads to electrolyte and metabolic imbalances,
which can cause bone loss. Furthermore, certain drugs taken by the patient may be reab‐
sorbed by the implanted bowel tissue, potentially leading to unintended toxic levels of these
substances within the bloodstream. The exposure of intestinal surface to urine also results
in the inappropriate absorption of ammonium, chloride and hydrogen ions as well as
potassium loss, leading to chronic metabolic imbalances or abnormalities.
• Infection. Persistent and recurrent infections are typical in patients with bowel tissue
reconstruction. Such infections may reach the kidney and become life-threatening. Addi‐
tionally, bacteria normally found in bowel tissue can serve as a source of infection and septic
complications when repositioned into the urinary tract.
• Stone formation. One of the consequences of persistent infection is the development of
stones. Stones are hard masses which can cause pain, bleeding, obstruction of urine or
infections.
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• Mucus. Bowel tissue, when repositioned in the urinary tract, continues to secrete mucus.
Mucus increases the risk of stone formation and the viscosity of urine, and in the case of
bladder augments, may require bladder irrigation and more frequent catheterization.
• Cancer. Malignancy, although rare, is a well-recognized complication following bladder
augmentation using bowel tissue (enterocystoplasty), as well as from other reconstructive
surgeries that incorporate bowel segments into the genitourinary tract.
In addition to cancers and developmental abnormalities, patients may present with neurogenic
bladder or dysfunctional bladder due to some form of neurologic disease or condition.
Treatment may often require an augmentation of the bladder in order to relieve high pressures
and incontinence. Current therapies for neurogenic bladder include medical management
through a combination of medication and clean intermittent catheterization and, in advanced
cases, surgery. Surgical procedures, such as bladder augmentation, are often considered when
other medical and less-invasive treatments fail to adequately lower bladder pressure or reduce
the frequency of incontinent episodes.
Ultimately, it is self-evident that the ideal unit of anastamosis for urinary-like tissue is other
urinary-like tissue. However, the lack of such material has generally precluded the widespread
leveraging of this option. There is therefore clearly a compelling medical need for an improved
approach that would eliminate or at least substantially reduce the complications potentially
associated with the current standard of care. To this end, identification of bladder-like
materials that may be applied towards bladder reconstruction in place of bowel tissue has been
attempted. Pilot experiments in 1917 to augment bladder in dogs leveraged fascia (Neuhof,
1917); since then, numerous other biomaterials candidates have been evaluated, including skin,
bladder sub-mucosa, small intestinal sub-mucosa, omentum, dura and peritoneum. Synthetic
materials candidates have included polyvinyl sponge, Teflon, gelatin, collagen, vicryl and
silicone. Failure to achieve successful outcomes with such biomaterials types may be attributed
to physical or mechanical failure, lack of biocompatibility and the induction of fibrosis and
scarring leading to contraction of the implant and reduction in effective volume over time.
Unfortunately, of these candidates the best biomaterial mimicking the physical and mechanical
properties of bladder tissue has been bowel. There is therefore a clear and present need for
additional, novel technology platforms.
3.1. TE/RM methodologies for bladder replacement and augmentation
Tissue engineering and regenerative medicine approaches offer an alternative, potentially
superior methodology to the use of bowel tissue for urinary diversion or replacement. In this
methodology, the patient’s own cells would be sourced from a bladder biopsy (or other,
alternate cell source, see below) and applied to an appropriate, degradable biomaterial scaffold
to create a neo-organ or organ-like construct that, upon implantation within the patient and
anastamosis to native components of the urinary system, would lead to regeneration of
functional, urinary-like neo-tissue capable of storing urine and mediating voiding of urine as
needed in response to appropriate neuronal signaling. Such a cell/biomaterial construct would
catalyze the regeneration of urinary-like neo-tissue recapitulating native, laminarly organized
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bladder wall histo-architecture composed of a luminal urothelial layer and multiple smooth
muscle layers, appropriately vascularized and innervated (Figure 3). Regeneration of urinary-
like neo-tissue is accompanied by progressive degradation of the biomaterial, such that a
seamless transition is achieved between the degrading biomaterial and the regenerating
urinary-like neo-tissue.
In preliminary experiments to demonstrate the formation of tissue engineered urothelial-like
structures in the rabbit, bladder-derived urothelial cells were used to seed meshes of non-
woven polyglycolic acid (PGA), which were subsequently implanted within the peritoneal
cavity of athymic mice. Upon recovery, structures composed of degrading biopolymer lined
with urothelial cells were observed (Atala et al., 1992). In follow-up studies, combinations of
bladder-derived smooth muscle cells and urothelial cells were used to seed tubular-like
structures composed of non-woven PGA mesh. Implantation of these constructs subcutane‐
ously within athymic rabbits led to regeneration of urinary-like tubular organoids composed
of urothelial cells lining a central lumen and surrounded by layers of smooth muscle cells, as
observed within native bladder tissue. Evidence of neo-vascularization was also noted (Atala,
et al., 1993). These studies provided preliminary proof of concept to support the potential for
in vivo regeneration of urinary-like neo-organs through implantation of cell seeded, synthetic
bio-polymeric scaffolds.
Although current strategies for creation of bladder-like neo-organs leverage principally non-
bladder cell sources, initial work on neo-bladder tissue engineering was dependent on patient-
derived bladder biopsies as a source of urothelial and smooth muscle cells. For this approach
to be commercially viable, the expansion dynamics of cellular growth for both biopsy-derived
urothelial and smooth muscle cell populations must be established. Although smooth muscle
cells could be reliably expanded from small bladder biopsies without difficulty, the demon‐
stration that a single biopsy-derived source of bladder urothelial cells could also be expanded
to the numbers required for effective seeding of urinary neo-organs was critical for establishing
the preliminary bioprocess potential of this methodology (Cilento, et al., 1994). The alternative
would involve multiple biopsy sampling to generate sufficient cell numbers for urinary neo-
organ seeding, greatly decreasing the attractiveness of this technology for practical application
in the clinic.
From a biomaterials perspective, the application of synthetic biopolymers such as PGA for the
seeding of urothelial and bladder-derived smooth muscle cells permitted development of
modified polymers with continuously tunable physical and mechanical characteristics. To this
end, the temporal sequence of polymer hydrolysis may be manipulated by altering the nature
and sequence of individual monomer units. In addition, coating by other polymers such as
PLGA may be applied to further fine-tune the physical properties of the biomaterial scaffold.
Finally, the open, fibrous networked structure of the biomaterial (Figure 4) facilitates angio‐
genesis and neo-vascularization of the developing neo-organ. Taken together, this binary cell/
synthetic biopolymer construct was the foundational technology platform needed for initiating
large animal clinical trials and proof-of-concept trials in man.
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Figure 4. Biodegradable PGA felt, with open “spaghetti”-like structure. 170X
3.2. Demonstration of Neo-Bladder formation in large animals
Subsequent to initial proof-of-concept studies showing de novo regeneration of urinary-like
structures in a small animal model (rabbit), the next step in successful process development is
evaluation of the technology in a large animal clinical model such as swine or dog. For the
Neo-Bladder Replacement, a key proof-of concept study was provided using a canine total
cystectomy (bladder removal) model. 14 beagles were sub-divided into three groups: A (n=2),
underwent cystectomy without further intervention. B (n=6) underwent cystectomy followed
by implantation with acellular, bladder-shaped biopolymer scaffold and group C (n=6) was
subjected to cystectomy and implantation with cell-seeded biopolymeric scaffold. To create
the constructs, PGA/PLGA biomaterial scaffolds (Figure 1) were shaped by hand into bladder-
shaped structures. Urothelial and smooth muscle cells were sourced from bladder biopsies
and expanded separately to numbers sufficiently meaningful to warrant seeding onto the
scaffolds (106 cells per cm2 of polymer surface). Urothelial cells were used to seed the interior,
luminal surface of the construct, and smooth muscle cells were applied to the exterior, non-
luminal surface.
Upon maturation, these constructs were implanted within group C animals. Implanted neo-
bladder constructs were wrapped extensively with omentum during surgery, as omentum is
a well-established source of pro-angiogenic growth factors (Litbarg, et al., 2007). All animals
were monitored over a period of up to 11 months post-implantation and extensive urodynamic
and radiographic measurements taken to document urologic functionality. At the completion
of the study period, animals were sacrificed and bladder-like structures examined histologi‐
cally for evidence of tri-laminar bladder wall architecture from regenerated neo-organs.
Structural and functional differences in regenerative outcomes were observed between all
three groups of canines. Group A dogs regained only minimal urinary reservoir volumes
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without approaching pre-cystectomy parameters. Group B dogs presented principally fibrotic
neo-bladders with a regenerated luminal urothelial cell layer but minimal regeneration of
bladder wall musculature. Urological dynamics were also significantly affected. This ability
of acellular constructs to regenerate a normal luminal urothelial cell layer is noteworthy,
providing a preliminary indication that prior seeding of constructs with urothelial cells may
not in fact be a requirement to achieve full regeneration of native-like urinary neo-tissue from
the implanted neo-organ construct. We will re-visit this observation and its implications later
in this chapter. However, canines implanted with cell seeded, bio-polymeric neo-bladder
constructs were able to regenerate histologically and functionally appropriate neo-bladders
with native-like tri-laminar wall histo-architecture and native-like urodynamics (Oberpen‐
ning, et al., 1999).
It may also be useful at this point to clearly define functional outcomes that are commonly
referred to as “regenerative” versus “reparative” in the context of TE/RM. Organ regeneration
involves the replacement and restoration of cellular components and fully developed tissue
mass as well as the reconstruction of the organizational, architectural and functional charac‐
teristics associated with the particular organ. In this regard, outcomes observed with group C
canines above are principally regenerative. In contrast, a reparative outcome is associated with
incomplete tissue replacement and may be distinguished by the extensive deposition of
collagen and concomitant fibrosis. Outcomes observed with group B canines represent
principally reparative pathways. This study and many others demonstrate clearly that
regenerative outcomes are mediated by cell seeded constructs only. Acellular constructs are
unable to catalyze neo-organ regeneration. This is an important foundational principle for
continued development of neo-organ regeneration technology.
Analysis of the dynamics of neo-bladder regeneration in subtotal cystectomized canines serves
to further illustrate the dichotomy in outcomes between implantation of acellular and cellu‐
larized scaffolds. In another such study, bladder shaped scaffolds composed of woven PGA
felt or PLGA (poly-lactic-co-glycolic acid) seeded with autologously sourced bladder-derived
urothelial cells and smooth muscle cells facilitated a regenerative response within one month
post-implantation, as characterized by induction of an extensively vascularized, smooth
muscle-like parenchyma. In contrast, acellular PGA/PLGA scaffolds triggered a principally
fibrotic, reparative outcome featuring disorganized collagen fibers with minimal vasculariza‐
tion. Baseline urodynamics were reconstituted within four months post-implantation with
cell-seeded scaffold, whereas urodynamic profiles of animals implanted with acellular
scaffolds remained abnormal throughout the nine-month study (Jayo, et al., 2008).
In a related cystectomized canine study, native-like tri-laminar bladder wall tissue architecture
was observed at three months post-implantation with a bladder shaped non-woven PGA felt
scaffold seeded with 1.5X108 each of autologously sourced bladder-derived urothelial cells and
smooth muscle cells, and normal compliance characteristics of a urinary bladder had devel‐
oped by 12 months. Regenerated bladders in animals receiving these cell-seeded scaffolds have
shown functional and structural stability for up to two years post-implantation. Importantly,
although the volume of the cell-seeded scaffold was held constant in this particular study,
implantation of the construct within dogs of different sizes that had gained varying amounts
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of weight over the course of the study yielded organs that, as measured by the ratio of bladder
capacity to body weight, adapted to the individual recipient animal’s size, demonstrating that
the regenerated neo-organ was capable of responding to homeostatic mechanisms regulating
organ volume (Jayo, et al., 2008).
3.3. Neo-bladder replacement in human pediatric patients-1st clinical trials of a neo-organ
Studies in canines as outlined above established proof-of-concept for the application of cell
seeded biodegradable polymeric scaffolds for regeneration of functional, native-like neo-
bladders in a large animal cystectomy model (Oberpenning, et al., 1999). Additional data
suggested that smooth muscle cells sourced from diseased bladder could potentially be
applied successfully to regenerate neo-urinary tissue (Lai, et al., 2002). These data laid the
groundwork for initiation of a proof of concept clinical trial in man. In this seminal study,
seven pediatric patients presenting with myelomeningocele (a form of spina bifida) were
recruited to receive the first ever human neo-organ implants. As previously described in
canines, both urothelial and smooth muscle cells were isolated and expanded from autolo‐
gously sourced bladder biopsies. Up to 5 cell passages over 7-8 weeks was required to generate
enough cells to seed the neo-bladder scaffold. Using a sterile pipette, the scaffold exterior was
seeded with bladder-derived smooth muscle cells at a seeding density of 5X107 cells/cm3. After
a 48hr recovery period, the luminal surface of the scaffold was seeded with urothelial cells at
a density of 5X107 cells/cm3. The construct was matured in a tissue culture incubator at 37
degrees C for 3-4 days, prior to implantation. Subsequent to implantation, the engineered neo-
bladder was cycled (i.e. subjected to serial volume expansion and contraction) as part of regular
post-operative care for up to 3 weeks post-implantation; the mechanical forces induced across
the neo-bladder during cycling have been found to augment regenerative outcomes. Engi‐
neered neo-bladders were found to functionally rescue urologic dynamics and were associated
with tri-laminar bladder wall architectures upon histological examination of bladder biopsies
recovered at 31 months post-implantation. A number of different scaffold iterations were
evaluated, with changes being made over the course of the study to accommodate new data
being made available from this and other related studies. Ultimately, an omentum wrapped,
collagen/PGA scaffold was found to present best overall regenerative outcomes (Atala, et al.,
2006).
3.4. Definition of the cell source used for seeding Neo-Bladders: Adipose
Adipose tissue contains a heterogenous mix of cell types, including adipocytes, endothelial
cells, pericytes, SMC, and MSC. Adherent cells that were derived from adipose tissue using
different conditions have been referred to as MSC without applying a systematic approach to
defining the isolated cell composition; however, distinctly different cell types can share
phenotypic characteristics. As more cell-based therapies move from preclinical to clinical
evaluation, establishing a cell composition profile that provides a degree of distinction from
other cell types will likely become increasingly important for protecting intellectual property
rights, gaining regulatory approval, and scaling up for manufacturing. The relevance of cell
type characteristics defined from analysis of native tissue or initial cell isolates to expanded
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cell populations is unclear because gene and protein expression patterns can be altered by
isolation and in vitro expansion. Such differences have been documented for MSC and we have
observed the same to be true for adipose-sourced smooth muscle-like cells (Ad-SMC).
The more important questions from a product development perspective are what character‐
istics are associated with the cell population that will be administered and how indicative are
those characteristics with regard to cell identity and product potency. Our comparison of Ad-
SMC and MSC leveraged established definitions of SMC and MSC and focused on the analysis
of smooth muscle phenotype, growth kinetics, in vitro tri-lineage differentiation bioactivity
and functional responses to small molecules that affect SMC-specific signaling pathways.
Unlike methodologies for MSC, isolation and expansion of Ad-SMC is specifically promoted
by growth of adipose SVF derived cells at low cell densities in the absence of positive/negative
selection through magnetic bead based separation, inductive cytokines or growth factors, high
serum (>10%) concentrations or preselected lots of serum. The specific influences of media
formulations on isolation and expansion of cells with MSC-like bioactivity has been extensively
documented (Basu, et al., 2011). Expansion of Ad-SMC is therefore the default outcome from
culture of SVF-derived cell populations in principally basal media formulations at high cell
densities not supplemented by inductive cytokines, preselected lots of serum or high concen‐
trations of FBS. This property greatly facilitates process development and manufacturing.
From where do Ad-SMCs originate and what is their relationship to MSC? Adipose is a heavily
vascularized tissue and a number of studies have implicated the perivascular niche as a
potential source of both MSC as well as smooth muscle and endothelial cells. Pericytes with
MSC differentiation potential have been isolated directly from blood vessels as well as from
multiple organ systems throughout the body. However, although ACTA2/SMAA+cells have
been localized to all capillaries, arterioles and venules of the adipose-derived vascular bed,
expression of STRO-1, a key MSC-specific marker, is tightly associated with endothelium and
additionally found only within a subset of blood vessels. Furthermore, expression of the stem
cell-specific markers Oct4 and telomerase was observed only rarely, suggesting that truly
pluripotent progenitors are uncommon within adipose. In their entirety, these observations
point to MSC, endothelium, and smooth muscle occupying distinct spaces within the broader
peri-vascular niche. Nevertheless, there remains the potential for considerable ebb-and-flow
across developmental lineages. For example, endothelial cells appear capable of lineage
switching towards a smooth muscle cell like phenotype in response to TGF-β or the depletion
of pro-angiogenic factors and loss of endothelial cell-cell contact. In addition, adherent cell
types with endothelial and smooth muscle phenotypes as well as limited mesenchymal
differentiation potential have been identified to circulate in adult peripheral blood. Such
circulating smooth muscle cells may contribute to the population of adipose-derived smooth
muscle cells, although we have been unable to purify them directly from human adult
peripheral blood in meaningful numbers (our unpublished observations).
Given that MSC in long term culture also follow a smooth muscle cell-like differentiation
pathway, we believe that taken together, the published data as well as our observations are
consistent with the peri-vascular niche of adipose SVF as a source for a broad continuum of
smooth muscle cells, smooth muscle progenitors, MSC and partially lineage committed MSC-
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like cell types with variable and overlapping degrees of proliferative and differentiation
potential. Modulation of SVF derived cell phenotypes and functionality away from MSC and
towards SMC is possible through selection of media formulations during cell isolation and
expansion. Our studies provide methodological validation for the utility of non-bladder
sources of smooth muscle-like cells for applications in urologic regenerative medicine, thereby
bypassing the potential for isolation and expansion of transformed SMC associated with
bladder biopsies derived from patients presenting with bladder-related malignancies.
3.5. Other approaches to tissue engineering Neo-Bladders
The sequential process development of the smooth muscle cell seeded/biodegradable synthetic
biopolymer scaffold neo-bladder regenerative platform as outlined above represents by far
and away the most clinically advanced such neo-organ product candidate developed to date.
No other methodology has even come close to clinical trials in humans or to commercial
manufacture. However, it is still worthwhile at this point to critically examine some alternative
approaches that have been presented in the literature and discuss why these have proven to
be ultimately unsuitable for commercialization.
From a biomaterials perspective, we have already discussed why the application of synthetic,
biodegradable polymers is preferable for industry. Briefly, such biomaterials may be sourced
or manufactured with defined chemical composition and offer reliable and reproducible
physical and mechanical properties that are continuously tunable by modification of basic
polymer chemistries. In contrast, naturally sourced biomaterials such as bladder-derived sub-
mucosa present variable chemical compositions that are donor specific, and may not be readily
sourced, as is in fact the case with human bladder-derived sub-mucosa.
This has led to the use of xenogeneically sourced biomaterials as substitute. Notwithstanding
the fact that porcine derived intestinal sub-mucosa is an established product for multiple
surgical applications, scaffolds made of decellularized bladder sub-mucosa were actually
evaluated in the first human neo-bladder clinical trials head to head against scaffolds com‐
posed of principally synthetic polymers (Atala, et al., 2006). The most favorable regenerative
outcomes were generated from implanted neo-bladders composed principally of PGA,
whereas the least favorable regenerative outcomes were observed within patients implanted
with neo-bladders constructs composed of decellularized bladder sub-mucosa. The course of
the clinical trial was appropriately modified to incorporate these findings. Taken together,
these observations reinforce the application of synthetic polymers over natural sourced
biomaterials for commercial viability.
From a cell sourcing perspective, a number of investigators are actively exploring the utility
of smooth muscle cells derived by the directed differentiation of MSC isolated from bone
marrow or adipose. A key characteristic of such stem and progenitor cell populations is a
requirement for exposure to combinations of exogenous growth factors, extracellular matrix
components, or other defined factors to drive differentiation along defined developmental
lineages. For example, in one recent report, adipose-derived MSC was differentiated into
smooth muscle-like cells using inductive media containing 100U/ml heparin for up to 6 weeks
prior to seeding polymeric bladder dome-like scaffold structures that demonstrated some
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evidence of functionality in a rat cystectomy model (Jack, et al., 2009). In additional, related
studies, TGF-β or small molecule agonists targeting the TGF-β signaling pathway (e.g.,
sphingosyl-phosphorylcholine, bradykinin and angiotensin II) have also been used to induce
a smooth muscle-like phenotype from adipose or bone marrow derived MSC (Gong, et al.,
2008; Kim, et al., 2008a; Jeon, et al., 2006; Kim, et al., 2008b). In a less targeted approach,
epigenomic reprogramming with the DNA demethylating agent 5-azaC, has been used to
direct bone marrow-derived MSC towards a cardiomyocyte-like phenotype (Xu,, et al., 2004).
Dedifferentiated adipocytes may also be driven along a smooth muscle lineage using TGF-β
and have been reported to contribute towards bladder tissue regeneration in a mouse bladder
injury model (Sakuma, et al., 2009). Finally, methods for TGF-β induced differentiation of
smooth muscle cells from bone-marrow derived cells have been described (Kanematsu, et al.,
2005; Becker, et al., 2008). These studies invariably involve demonstrations of in vitro directed
differentiation of SMC-like cells derived from MSC, using various combinations of growth
factors and cytokines over an extended time period. Any in vivo data is typically based in small
animals, is often subcutaneous and therefore of little relevance to product development and
manufacturing.
Finally, the use of the peritoneal cavity as a living bioreactor for maturation of tubular organs
has been proposed. It is well established that implantation of foreign material into the
peritoneal cavity may frequently trigger a fibrotic response, with encapsulation of the foreign
matter by multiple layers of fibroblasts. We have observed similar, non-regenerative outcomes
associated with implantation of certain synthetic biopolymers such as poly-caprolactate within
the renal parenchyma (Basu et al., 2012). However, this normally unwelcome outcome might
be leveraged for induction of tubular neo-tissue formation.
In the first such demonstration of this approach, silastic tubing was implanted into the
peritoneal cavity of rats/rabbits. At 2 weeks post-implantation, the tube was observed to be
coated with several layers of myofibroblasts, collagen and a layer of mesothelium. Removal
of the silastic tube followed by eversion of the cellular construct resulted in formation of a
vessel-like structure, with laminar wall architecture mimicking that of native vasculature.
Anastamosis of this neo-vessel with the vasculature of the original host animal demonstrated
evidence of function and patency for up to 4 months post-implantation (Campbell, et al., 1999).
Similarly, neo-organs resembling bladder, uterus and vas deferens could be engineered by
grafting biomaterials templates of appropriate shape within the peritoneal cavity of rabbits.
After 2-3 weeks of implantation within the environment of this “living bio-reactor”, neo-organ
like frameworks composed of myo-fibroblastic layers could be harvested and grafted onto the
appropriate organs of the original host to demonstrate functionality and eventual regeneration
of urinary-like tissue (Campbell, et al., 2008). Although interesting, it is difficult to envision
how such a strategy can ever be feasible in practice. Clearly, undergoing major surgery and
all associated post-operative care and monitoring simply to create the neo-organ implant will
not be an attractive option, given the alternatives currently under development. Therefore, we
do not anticipate that tissue engineering of bladder using the peritoneal cavity as a living
bioreactor will become a commercially viable strategy.
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3.6. Key learnings from development of Neo-Bladder: Factors facilitating commercial
viability of organ regeneration platform
The Neo-Bladder experience at Tengion highlights certain key factors that may impact the
commercial success of an organ regeneration platform. These same principles are pertinent to
discussion of non-bladder tubular organs as well as to regenerative technologies targeting solid
organs such as kidney, liver and pancreas. We outline these principles below:
1. A biodegradable, synthetic scaffold based on well-characterized biomaterials (e.g., PGA,
PLGA) that can be manufactured reproducibly with defined characteristics is desirable.
2. A population of committed cell types (e.g., smooth muscle cells) that is easily isolatable
and expandable is required for scaffold seeding to trigger regeneration in vivo.
3. A purified population of defined stem cells in neither needed nor desirable. Cost of goods
increases significantly with requirements to monitor stem cell potential and to control
directed differentiation.
4. Engineering of an entire organ in vitro or within the peritoneal cavity is neither needed
nor desirable. Instead, an in vitro cell seeded scaffold is adequate to trigger the innate
regenerative response in the mammalian body, resulting in de novo organogenesis in
vivo, including in humans.
4. Neo-urinary conduit: Introduction
The possibility of creating a TE/RM product facilitating urinary diversion without leveraging
native GI tissue was the rationale underlying the development of the Neo-Urinary Conduit
(NUC). In its simplest configuration, the NUC is a cell/scaffold construct that, upon implan‐
tation within the body and attachment to native ureters, mediates efflux of urine from the
kidneys directly to the external surface of the body. As with the Neo-Bladder Replacement and
related TE/RM products, the NUC construct serves as a template to catalyze the regeneration
of native-like urinary tissue concomitant to degradation of the biomaterial scaffold following
implantation.
4.1. GLP preclinical analysis of de novo neo-urinary conduit formation in a porcine
cystectomy model
32 Gottingen swine with total cystectomy and incontinent ureterostomy (8 animals per data
point composed of 4 males and 4 females each) were used in a GLP preclinical analysis to
determine the safety and functionality of tissue-engineered NUC constructs seeded with
autologous smooth muscle cells derived from the bladder, blood or adipose tissue. Of the 32
animals, the first group (4 males, 4 females) was implanted with NUC seeded with bladder-
derived smooth muscle cells. A second group was implanted with NUC scaffold seeded with
adipose-derived SMCs, a third group was implanted with a NUC scaffold seeded with blood-
derived SMCs, and the 4th group was implanted with unseeded NUC scaffold only. Device
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effect and performance was monitored through ultrasound imaging, pyelogram, as well as
urine and blood analysis at different time-points of the study. At the completion of the recovery
period (Day 84+/-5), all animals were euthanized and a necropsy performed for harvesting the
kidneys, conduits, and associated organs and tissues for histological preparation and patho‐
logical examination.
4.2. Alternate cell sourcing of SMC for seeding of NUC
Tissue engineering principles have been successfully applied to provide implantable cell-
seeded matrices for use in the reconstruction, repair, augmentation or replacement of lamina‐
rily organized luminal organs and tissue structures, such as a bladder or a bladder segment
or component, typically composed of urothelial and smooth muscle layers. Smooth muscle
cells may be derived from the patient’s own tissue, including the bladder, urethra, ureter and
other urogenital tissue. However, there are challenges associated with dependence upon the
development and maintenance of cell culture systems from the primary organ site as the basic
unit for developing new and healthy engineered tissues, as for example during treatment of
cancerous bladder tissue. Clearly, such cancerous cells are inappropriate for populating an
implantable neo-bladder scaffold or matrix. We have therefore attempted to identify and
characterize alternative sources of smooth muscle cells capable of reconstituting urologic
characteristics de novo upon implantation on appropriate synthetic, biopolymer scaffold
constructs, and to demonstrate functionality in vivo.
Numerous studies have indicated that adherent, fibroblast-like cells with typical smooth
muscle cell characteristics may be recovered from the mononuclear fraction of peripheral
blood, cord blood or bone marrow. These smooth muscle-like cells may be pericytes, which
are recruited to developing arterioles, capillaries and venuoles. Additionally, it is well
established that adipose tissue is a readily available source of adherent cell types and may
therefore also represent an alternative source of smooth muscle cells useful for urologic
application. Indeed, adipose isolated during abdominoplasty precedures is rich with capilla‐
ries, providing a potential source of isolatable smooth muscle-like pericytes. Although smooth
muscle cells have also been isolated from other tissue sources such as skeletal muscle and
omentum, we chose to focus on recovery of smooth muscle cells from peripheral blood and
adipose, as these represent the source tissue with maximum potential clinical utility. A porcine
cystectomy model was selected to evaluate the performance of peripheral blood and adipose-
derived smooth muscle cells relative to bladder-derived smooth muscle cells upon application
in a cell/scaffold composite.
Direct plating of the peripheral blood-derived mononuclear fraction from swine resulted in
outgrowth of colonies with typical smooth muscle cell morphology. 100% of animals screened
(n=24) generated smooth muscle cell colonies, with 2.44 X103-2.37 X106 smooth muscle cells
recovered at passage zero from 50mls of peripheral blood. Recovery of smooth muscle cells
was unaffected by changes in media formulation, cell density or surface coatings (data not
shown). A similar approach was used to investigate the potential application of subcutaneous
or lipoaspirate-derived adipose as a source of smooth muscle cells. The stromal-vascular
fraction (SVF) of adipose represents a heterogenous population of cells including endothelial
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cells, smooth muscle cells as well as progenitor cells with limited mesenchymal potential. We
were able to generate colonies (expandable into monolayers) of smooth muscle cells from
porcine adipose with 100% efficiency (n=24), with a cell recovery rate of 1.37 X105-4.36 X105
cells/g adipose tissue. In comparison, smooth muscle cells could be isolated from bladder tissue
with a recovery rate of 1.29 X106-9.3 X106 cells/g bladder tissue. Expansion of smooth muscle
cell colonies from peripheral blood or adipose resulted in the formation of a cell monolayer
with a typical whirled, “hill-and-valley” organization characteristic of cultured bladder-
derived smooth muscle cells (Figure 5). Enrichment of smooth muscle cells was facilitated by
use of high cell densities and high glucose media, which has been shown to specifically select
against the growth and expansion of mesenchymal stem cells (Basu, et al., 2011).
Figure 5. Healthy SMC in culture present a well-established appearance of flattened, spindle-like, fibroblastic mor‐
phology, with characteristic “hill-and-valley” organization.
Analysis of the functional properties of peripheral blood or adipose-derived smooth muscle
cells in vitro demonstrates that they are indistinguishable from bladder-derived smooth muscle
cells. Increased expression of proteins associated with smooth muscle contractility is a
characteristic feature of smooth muscle cell differentiation and maturation. Myocardin is a key
transcription factor required for smooth muscle cell differentiation and acts to mediate the
expression of smooth muscle markers essential for contractility including SM22, α-smooth
muscle actin (SMαA), smooth muscle myosin heavy chain (SMMHC) and calponin (CNN).
Expression of the smooth muscle markers SMMHC and CNN is generally regarded as
diagnostic of mature smooth muscle cells.
Application of adipose and peripheral blood-derived smooth muscle cells for urologic
regenerative medicine is contingent on being able to secure adequate cell numbers within an
acceptable time frame. Towards this end, we have observed that smooth muscle cell colonies
(from a 50ml sample of porcine peripheral blood or 7-25g porcine adipose) are identifiable
within 7 days post seeding, and may be passaged within 14 days. In fact, tens of millions of
smooth muscle cells may be recovered from bladder, peripheral blood or adipose within 2-4
weeks (n=24). Bladder and adipose-derived smooth muscle cells were expanded for 2 passages
prior to harvesting of cells for seeding a synthetic, neo-urinary conduit scaffold. Peripheral
blood-derived smooth muscle cells were expanded for 3-4 passages to generate equivalent cell
numbers. On average, 30-40 X106 smooth muscle cells were used to seed a neo-urinary conduit
scaffold.
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We have previously shown that bladder-derived smooth muscle cells may be used to seed a
synthetic, biopolymer scaffold which upon implantation into an in vivo clinical model of
bladder cystectomy resulted in the regeneration of a fully functional de novo bladder augment
(Jayo, et al., 2008a,b). However, because use of bladder-derived smooth muscle cells may not
be clinically ideal, we proceeded to evaluate the in vivo clinical efficacy of peripheral blood
and adipose-derived smooth muscle cells in a 3 month porcine clinical model of urinary
incontinence. Bladder, adipose and peripheral blood-derived smooth muscle cells were used
to seed PGA/PLGA-based scaffolds to create a regenerative, neo-urinary conduit permitting
efflux of urine from the ureters directly to the external body surface.
We observed that constructs composed of smooth muscle cells obtained from blood or bladder
sources regenerated a patent conduit composed of an urothelial cell lining and smooth muscle
layer that did not result in alterations to the upper urinary tract. No evidence was found for
elevated creatinine, metabolic abnormalities or altered hematological parameters. Histological
characteristics of the regenerated urological tissue forming the neo-urinary conduit were
generally similar regardless of the origin of the smooth muscle cell population. In contrast,
scaffold-only implanted animals developed patent urothelial-lined conduits composed
primarily of fibrous connective tissue and limited smooth muscle development. This group
also had a high frequency of hydroureter and hydronephrosis. In both groups, early post-
operative management of the conduit lumen and stoma was required to maintain patency for
the study duration (Basu, et al., 2012).
This study demonstrates that a synthetic, biopolymeric scaffold composite seeded with
autologous smooth muscle cells derived from multiple potential cell sources (blood, fat or
bladder) is capable of being used to re-create a patent neo-urinary conduit. The regenerated
conduit was not associated with sequela commonly found with urinary diversions generated
from intestinal tissue or with non-cell seeded synthetic scaffolds. This ability to create urologic
structures de novo from synthetic scaffolds seeded by peripheral blood or adipose-derived
smooth muscle cells will greatly facilitate the translation of urologic tissue engineering
technologies into clinical practice.
4.3. Clinical trials of NUC
Based on successful outcomes in GLP porcine cystectomy models as outlined above, Tengion
has initiated Phase I clinical trials of NUC constructs in human patients requiring urinary by-
pass. This Phase I study “Incontinent Urinary Diversion Using an Autologous Neo-Urinary
Conduit” is currently recruiting patients (as of time of writing), with the objective of implanting
up to 10 patients by 2015. The objective of the study is to evaluate if NUC constructs, made in
the laboratory by a combination of the patient’s own adipose derived smooth muscle cells in
combination with defined, degradable biomaterial scaffolds, may be used to form a functional
conduit to safely facilitate passage of urine from kidneys to outside the body subsequent to
radical cystectomy in patients presenting with bladder cancer.
Primary outcome indices over a 12 month post-implantation timeframe include structural
integrity and conduit patency. CT scans will be used to demonstrate that urine may flow safely
through the NUC construct. Additional measures of primary outcomes up to 12 months post-
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implantation include an evaluation of any product or procedure related adverse events.
Similarly, secondary outcome indices will include analysis of NUC structural integrity and
patency over a 12-60 month post-implantation timeframe. CT scan and renal ultrasound will
be applied to demonstrate that urine is able to flow safely through the NUC construct up to
60 months post-implantation. Procedural and product related adverse events will also be
monitored to 60 months post-implantation. Finally, the overall safety of the NUC construct
will be assessed through evaluation of non-product/procedural related adverse events and
patient vital signs. Eligibility for this clinical trial has been adjusted to be as inclusive as possible
while ruling out any patients that present with secondary conditions likely to negatively
impact regenerative outcomes:
4.4. Regeneration of muco-cutaneous region at skin-conduit junction
Successful implantation of NUC requires the regeneration of a native-like muco-cutaneous
region at the skin/conduit junction following implantation. A muco-cutaneous junction is a
region where the luminal mucosa transitions to skin. Such muco-cutaneous junctions occur
throughout the body at orifices including mouth, nostrils, anus, eyelids and components of
the genito-urinary system. Typically, such junctions involve transitioning of epithelium to
epidermis, lamina propia to dermis and smooth muscle to skeletal muscle. An in vitro tissue
engineered human lip-like element reproducing the transitional morphology of human lip
including epidermal skin, vermillion and oral mucosa has recently been reported (Peramo et
al., 2012). This observation notwithstanding, it should be appreciated that the regeneration of
a muco-cutaneous junction at the skin/conduit interface of a synthetic neo-organ such as the
NUC has never before existed in nature. This indicates that context-appropriate signaling
between construct and host is nevertheless possible leading to regeneration of cell types
relevant to the neo-organ.
In the case of the urinary system, urine exits the body via the urethral meatus, a distinct structure
incorporating features that defend the opening against local and/or ascending infections,
emptying into the vaginal vestibule in females and the fossa navicularis in males. Specifically,
this muco-cutaneous junction is a non-keratinized, stratified squamous epithelium composed
of glycogen rich cells that provide substrate for a protective endogenous lacto-bacterial flora.
Also, as the epithelium nears the skin, it is associated with acid phosphatase activity and
lysozyme-like immuno-reactivity indicative of the presence of macrophages that secrete
bacterial compounds. In the pre-clinical study in cystectomized pigs discussed previously,
implanted NUC was observed to catalyze formation of a native-like transition between the
urinary mucosa and skin epithelium with structural features resembling that of muco-
cutaneous junctions observed in native urethras (Basu et al., 2012a). These observations
demonstrate that the de novo regeneration of transitional junctions including muco-cutaneous
junctions may be catalyzed by regenerative constructs such as Tengion’s Organ Regeneration
PlatformTM, opening the door to regeneration of components of the gastro-intestinal tract,
where many such transitional zones are located.
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5. The gastro-intestinal tract: Introduction
Individual components of the GI represent locally specialized, iterative variations of essentially
the same laminarly organized tubular histologic architecture as the bladder, and therefore
should be amenable to regenerative therapies based on the same platform technologies
successfully applied to the bladder. However, from a commercial perspective, the small
intestine represents by far the most pressing current clinical need, with small bowel trans‐
plantation representing an unsatisfactory current standard of care for pediatric small bowel
syndrome (SBS) (http://digestive.niddk.nih.gov/ddiseases/pubs/shortbowel/). Additionally,
esophageal replacement or augmentation for esophageal cancer may also be commercially
viable.
Signaling interactions between endodermal epithelium and mesenchymal cells derived from
splanchic mesoderm mediate axial differentiation of the primitive gut tube during embryo‐
genesis into distinctive functional domains. These individual components of the GI including
the oral cavity, esophagus, stomach, small intestine and colon represent locally specialized
iterative variations of essentially the same laminarly organized tubular histologic architecture
as the bladder. The molecular genetics underlying these differentiative signaling cascades is
complex, but is broadly understood to involve members of the hedgehog family of ligands,
including sonic hedgehog, desert hedgehog and indian hedgehog. Hedgehog proteins bind the multi-
pass transmembrane receptor patched-1, thereby blocking patched-1-mediated inhibition of the
seven-pass membrane protein smoothened. Smoothened-mediated signal transduction regulates
the transcriptional response to hedgehog activation within the target tissue. In mouse models
and human patients, mutations in hedgehog signaling proteins and downstream targets lead to
a variety of severe malformations of the GI tract. Genetic analysis of GI formation has been
extensively reviewed in detail elsewhere (Van den Brink, 2007). Conservation of signaling
between mesenchymal and epithelial cell populations during organogenesis of bladder and
GI suggests that the organ regeneration platform appropriate for bladder regeneration may
also function in an independent positional context to catalyze regeneration of the GI, including
but not limited to small intestine and esophagus.
The intestinal epithelium is the most highly regenerative tissue within adult mammals and
may therefore be expected to be most amenable towards tissue engineering or regenerative
medicine methodologies. Perhaps the best described strategy for regeneration of intestine and
other components of the gastrointestinal tract involves the use of in vivo derived organoid
units, formed from incompletely disassembled clusters of epithelial and mesenchymal cells
generated through partial digestion of intestinal epithelium and therefore likely incorporating
resident intestinal stem cells. In one such study, autologous organoids were derived from the
intestine of 6 week old mini-pigs and used to seed PLLA scaffold tubes that were subsequently
matured within the peritoneal cavity of the original donor. Seven weeks post-implantation,
this tissue-engineered small intestine recapitulated the gross overall laminar organization of
native small intestine (SI) (Sala, et al., 2009). Significantly, acellular scaffolds did not result in
the regeneration of tissue engineered gastrointestinal structures. These data notwithstanding,
anastamosis of these tissue engineered small intestines to host SI within a large animal model
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remains to be demonstrated. Additionally, up to 10cm of host SI was harvested to derive donor
organoids that are not readily expandable in vitro. Whether organoid units capable of seeding
a scaffold structure may be isolated from diseased human intestine, and how much diseased
donor material may be needed, remain factors yet to be elucidated. The requirement to leverage
the peritoneal cavity as a bioreactor for tissue engineering may also impede widespread
application of this approach. The bladder-derived organ regeneration platform of bio-
polymeric scaffold seeded with smooth muscle cells may be applicable for regeneration of SI.
To this end, stomach derived smooth muscle cells were used to seed a collagen-based scaffold
prior to implantation within surgically isolated ileal loops of dogs for eight weeks, prior to re-
anastamosis to the native intestine. Acellular collagen scaffold was used as a control. By 12
weeks post-surgery, macroscopic analysis of the cell seeded scaffold implantation site
demonstrated regeneration of neo-mucosa resembling native mucosa. However, in animals
containing an acellular scaffold, the implant site remained ulcerated up to 12 weeks post-
implantation. Additional histological data showed significantly enhanced vascularization,
epithelialization and organization of the circular muscle layer at the cell seeded scaffold defect
site relative to acellular control (Nakase, et al., 2006).
Increasing the number of smooth muscle cells seeded onto the scaffold increased the area of
regenerated SI tissue, although no concomitant increase in the thickness of the smooth muscle
layer was observed (Nakase, et al., 2007). Nevertheless, these data suggest that a simple
regenerative platform composed of biodegradable scaffold nucleated with smooth muscle cells
may be adequate to facilitate SI regeneration. Although this approach must be reproduced
using a directly anastamosed tubular scaffold and alternate sources of smooth muscle cells, if
successful, this methodology represents the most straightforward, clinically relevant and
commercially viable strategy for regeneration of the SI. This organ regeneration platform
technology may also be leveraged for regeneration of the esophagus. In one such example,
patch defects were created in the abdominal esophagus of 27 female rats, subsequently
implanted with gastric acellular matrix (GAM). Of the 24 survivors, none showed evidence of
regeneration of the lamina muscularis mucosa even 18 months post-implantation (Urita, et al.,
2007). In contrast, a study of a canine model of esophageal resection and replacement demon‐
strated that PGA tubes seeded with a mixture of keratinocytes and fibroblasts triggered
regeneration of smooth muscle laminar organization similar to native esophagus within 3
weeks post-implantation, whereas acellular PGA tubes formed esophageal strictures were
associated with near complete obstruction within two to three weeks (Nakase, et al., 2008). In
another dog study, cervical esophageal defects were patched with either small intestinal
submucosa (SIS) alone, or SIS seeded with autologous oral mucosal epithelial cells. After four
weeks, dogs implanted with cell seeded SIS showed almost complete re-epithelialization and
minimal evidence of inflammation and, by eight weeks post-surgery, regeneration of the
underlying smooth muscle layer. Acellular SIS grafted animals presented only partial re-
epithelialization and a more extensive inflammatory response by four weeks, and no muscular
regeneration by eight weeks. Attempts to introduce an acellular SIS tubular construct into the
cervical esophagus of piglets were also unsuccessful, demonstrating scarification and a
minimal regenerative response (Doede, et al., 2009).Progress has also been made in efforts to
tissue engineer the stomach. Stomach derived organoid units, (analogous to the SI organoids
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used to tissue engineer the SI) upon seeding of a biopolymeric scaffold, triggered reconstitution
of the gastric and muscularis mucosa in stomach tissue engineered within the peritoneal
cavities of swine (Sala, et al., 2009). In another study, circular defects were created in the
stomach of seven dogs and a composite biodegradable scaffold (“New-sheet”), soaked with
either autologous peripheral blood or bone marrow aspirate, was sutured over the defect. By
16 weeks post implantation, the defect site had formed regenerated stomach with evidence of
re-epithelialization, formation of villi, vascularization and fibrosis within the sub-mucosal
layer. However, minimal regeneration of the smooth muscle layer was observed, as shown by
expression of smooth muscle α-actin, though not calponin, a marker of mature smooth muscle
cells (Araki, et al., 2009).Though strictly not a tubular organ, the anal sphincter is a component
of the gastrointestinal tract and is critical in regulating patency of the large intestine. Recent
efforts to engineer the anal sphincter leverage the same general platform used to catalyze
bladder regeneration. To this end, smooth muscle cells isolated from human internal anal
sphincter were seeded onto fibrin gels poured around a central mold. Cell mediated contrac‐
tion of the gel around the mold resulted in the formation of a 3D cylindrical tube of sphincteric
smooth muscle tissue. Although in vivo anastamosis remains to be demonstrated, this bio-
engineered anal sphincter demonstrated contractile properties and response to defined
neurotransmitters consistent with the functionality of native anal sphincter (Somara, et al.,
2009; Hashish, et al., 2010). Use of alternatively sourced smooth muscle cells may facilitate the
transition of engineered sphincter towards commercial production.
Preclinical rodent studies were initiated in our laboratory to evaluate the ability of constructs
composed of smooth muscle cell seeded PLGA coated PGA patches to support regeneration
of esophagus. In these studies, small (3-5 mm2) defects were introduced within the esophagus
of rodents, such that the entire esophageal wall was removed within the defect. Injuries were
subsequently repaired with cell seeded patch constructs and allowed to regenerate in vivo for
up to 10 weeks post-implantation. Evidence of early regenerative outcomes was observed at
8 days post-implantation in the form of developing bundles of smooth muscle. Complete
regeneration of longitudinal and circularly oriented musculatures and luminal epithelia were
observed at 10 weeks post-implantation of construct. Importantly, as with previous studies,
vascularization of the regenerative construct by wrapping with omentum during implantation
was crucial for a successful regenerative outcome. These small animal data establish the utility
of SMC coated PGA felt-based biomaterials for tissue engineering and regeneration of the
esophagus (Basu et al., 2012b; Basu et al., 2013).
For the small intestine (SI), patch based constructs composed of adipose derived smooth
muscle cell seeded PGA felts were observed to support full regenerative outcomes upon
implantation within rodent models of SI injury. Regeneration of intestinal epithelia with micro-
villi as well as regenerated bundles of smooth muscle cells were observed within 3 months
post-implantation. Studies were also initiated to evaluate the regenerative potential of cell
seeded biomaterials constructs within the context of a tube. In addition to supporting the
proliferation and migration of SI derived cells, such tubular constructs must have appropriate
physical and mechanical properties that complement those of native tissue. In particular,
within the GI tract, tubular constructs must be capable of supporting peristaltic movement of
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food or fecal matter. Commercially sourced PGA braided tubes were observed to have physical
properties reminiscent of SI, and were therefore applied in the context of tubular cell seeded
constructs for evaluation of regenerative outcomes within rodent SI. As with the patch,
complete regeneration of intestinal epithelia and partial regeneration of bundles of smooth
muscle cells was observed at 3 months post-implantation. Implanted animals were capable of
eating normally, gained weight and passed fecal material in a manner comparable to healthy
controls. A detailed analysis of regenerative outcomes in rodents implanted with SMC seeded
tubular constructed has been previously presented (Basu et al., 2011b). As with all other tubular
organs, presence of a cellular component on the regenerative construct is essential to a
successful regenerative outcome. This data notwithstanding, observed difficulties in regener‐
ation of SI musculature from simple constructs derived from biomaterials used in bladder
regeneration suggest that there are elements unique to SI currently missing from the current
generation of construct prototypes. One such potential factor is the role of the enteric nervous
system in facilitating regenerative outcomes within the GI tract.
6. Summary
1. Tengion’s foundational Organ Regeneration PlatformTM composed of adipose-sourced
smooth muscle cells complexed with a synthetic, biodegradable scaffold, is broadly
applicable to regeneration of multiple tubular organs.
2. Constructs function by manipulating fundamental signaling pathways between mesen‐
chymal and epithelial cell populations to trigger regenerative outcomes mimicking
organogenesis during development and regeneration in organisms such as urodeles,
including induction of a neo-blastema.
3. Tubular organ regeneration is influenced by adequate vascularization and cellular
constituents present at the local site.
4. Mucosal regeneration is influenced by blood supply with organ specific events controlling
biological events.
This ability to apply the same fundamental signaling elements that mediate the regenerative
process through application of the same combination of cells and biomaterials towards
regeneration of multiple tubular neo-organs will greatly facilitate development of a manufac‐
turing platform with commonalities throughout bio-processing.
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